TY - JOUR
T1 - The evolving field of nephrology
T2 - what comes next? A report from the European Renal Association Scientific Advisory Board
AU - Kanbay, Mehmet
AU - Copur, Sidar
AU - Capasso, Giovambattista
AU - Turkmen, Kultigin
AU - Delanaye, Pierre
AU - Bruchfeld, Annette
AU - Abd ElHafeez, Samar
AU - Ferro, Charles J
AU - Verhaar, Marianne C
AU - Pesce, Francesco
AU - Liakopoulos, Vassilios
AU - Boor, Peter
AU - Adamczak, Marcin
AU - Vivarelli, Marina
AU - Navarro-González, Juan F
AU - Kramann, Rafael
AU - Florquin, Sandrine
AU - Valdieso, Jose Manuel
N1 - Publisher Copyright:
© The Author(s) 2026. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2026/5
Y1 - 2026/5
N2 - The field of nephrology is rapidly expanding and evolving with advancements in the areas of diagnostics including biomarkers, molecular genetics and imaging modalities, and therapeutics. As acute kidney injury affects a substantial proportion of hospitalized patients with considerable morbidity and mortality risk and chronic kidney disease is among the leading causes of morbidity and mortality globally, the advancements in the field of nephrology are worth focusing on and highlighting. Novel biomarkers along with better imaging modalities, including functional tools such as positron emission tomography and contrast-enhanced ultrasound, may enable earlier diagnosis of kidney injury and potentially reverse injury state before the establishment of an irreversible state of injury. Moreover, there are multiple ongoing clinical trials evaluating novel therapeutic approaches, advancements in kidney replacement therapies or targeted approaches against kidney transplantation including xenotransplantation and plasma cell-directed therapies. In addition, artificial intelligence may become a game changer in nephrology, providing improved diagnostic and therapeutic alternatives. However, the limitations of current state of knowledge in those novel modalities should be adequately acknowledged and addressed. In this narrative review, our aim is to evaluate the current state of advancements in the field of nephrology in terms of diagnostics, imaging modalities, biomarkers, and therapeutics along with providing potential future perspectives.
AB - The field of nephrology is rapidly expanding and evolving with advancements in the areas of diagnostics including biomarkers, molecular genetics and imaging modalities, and therapeutics. As acute kidney injury affects a substantial proportion of hospitalized patients with considerable morbidity and mortality risk and chronic kidney disease is among the leading causes of morbidity and mortality globally, the advancements in the field of nephrology are worth focusing on and highlighting. Novel biomarkers along with better imaging modalities, including functional tools such as positron emission tomography and contrast-enhanced ultrasound, may enable earlier diagnosis of kidney injury and potentially reverse injury state before the establishment of an irreversible state of injury. Moreover, there are multiple ongoing clinical trials evaluating novel therapeutic approaches, advancements in kidney replacement therapies or targeted approaches against kidney transplantation including xenotransplantation and plasma cell-directed therapies. In addition, artificial intelligence may become a game changer in nephrology, providing improved diagnostic and therapeutic alternatives. However, the limitations of current state of knowledge in those novel modalities should be adequately acknowledged and addressed. In this narrative review, our aim is to evaluate the current state of advancements in the field of nephrology in terms of diagnostics, imaging modalities, biomarkers, and therapeutics along with providing potential future perspectives.
U2 - 10.1093/ckj/sfag136
DO - 10.1093/ckj/sfag136
M3 - Review article
C2 - 42182977
SN - 2048-8505
VL - 19
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 5
M1 - fag136
ER -